News

HERZLIYA, Israel and CALGARY, Alberta, July 23, 2025 /PRNewswire/ -- Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that ...
Innocan Pharma Corporation ("Innocan" or the "Company") (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) is pleased to announce that it has publicly filed a registration statement on Form F-1 with the U.S.
Current approaches in bioengineering are synthesized and methods for their implementation are suggested for the induction and modulation of trained immunity in the treatment of human diseases.